LOS ANGELES and NIMES, France, May 02, 2024 (GLOBE NEWSWIRE) -- Aanastra, Inc., a biopharmaceutical company focused on developing RNA therapeutics leveraging its peptide delivery technology for targeting cancers and other genetic diseases, today announced multiple presentations at the 2024 American Society for Gene and Cell Therapies (ASGCT), taking place May 7-11, 2024, in Baltimore, MD..

洛杉矶和法国尼姆，2024年5月2日（环球通讯社）--Aanastra，Inc.，一家专注于开发利用其肽递送技术靶向癌症和其他遗传疾病的RNA疗法的生物制药公司，今天宣布在2024年5月7日至11日于马里兰州巴尔的摩举行的2024年美国基因和细胞疗法学会（ASGCT）上进行多次演讲。。

ASGCT presentation details are below:

ASGCT演示详细信息如下：

Title (Poster): 'Peptide Based Nanoparticle-Platform for Extrahepatic Delivery of Functional mRNAs'

标题（海报）：“用于肝外递送功能性mRNA的基于肽的纳米颗粒平台”

Session Title: Other Nonviral Delivery

会议标题：其他非病毒交付

Location: Exhibit Hall

地点：展厅

Abstract Number: 761

摘要编号：761

Date/Time: Wednesday May 8, 2024, 12:00 PM

日期/时间：2024年5月8日星期三下午12:00

Presenting Author: DIVITA Gilles, PhD

演示作者：DIVITA Gilles博士

Title (Poster): 'Peptide-Based Nanoparticles Mediated mRNA Rescue of Factor VIII; a New Approach to Treat Hemophilia A'

标题（海报）：'基于肽的纳米颗粒介导的因子VIII的mRNA拯救；治疗血友病a'的新方法

Session Title: Liver Genetic Diseases

课程名称：肝脏遗传性疾病

Location: Exhibit Hall

地点：展厅

Abstract Number: 1093

摘要编号：1093

Date/Time: Thursday May 9, 2024, 12:00 PM

日期/时间：2024年5月9日星期四下午12:00

Presenting Author: DIVITA Gilles, PhD

演示作者：DIVITA Gilles博士

Title (Poster): 'In Vivo CRISPR Mediated Editing of PCSK9 Using Peptide-Based Nanoparticles Durably Lowers Cholesterol in Mice'

标题（海报）：“使用基于肽的纳米颗粒在体内CRISPR介导的PCSK9编辑可持久降低小鼠的胆固醇”

Session Title: Liver Genetic Diseases

课程名称：肝脏遗传性疾病

Location: Exhibit Hall

地点：展厅

Abstract Number: 1094

摘要编号：1094

Date/Time: Thursday May 9, 2024, 12:00 PM

日期/时间：2024年5月9日星期四下午12:00

Presenting Author: DIVITA Gilles, PhD

演示作者：DIVITA Gilles博士

Title (Oral Presentation): 'KRAS Mutant Gene Editing Abolishes Tumor Growth In Vivo and Overcomes Acquired Resistance to KRASG12C and KRASG12D Small Molecule Inhibitors'

标题（口头介绍）：“KRAS突变基因编辑消除了体内肿瘤的生长，克服了对KRASG12C和KRASG12D小分子抑制剂的获得性耐药”

Session Title: Targeted Gene and Cell Therapy II

课程名称：靶向基因与细胞疗法II

Location: Room 318-323

地点：318-323室

Abstract Number: 415

摘要编号：415

Date/Time: Saturday May 11, 2024, 10:15 AM - 12:00 PM

日期/时间：2024年5月11日星期六上午10:15

Presenting Author: DESAI Neil, PhD

演示作者：DESAI Neil博士

More information can be found on the ASGCT meeting website.

更多信息可以在ASGCT会议网站上找到。

About Aanastra, Inc.

关于Aanastra，股份有限公司。

Aanastra Inc (formerly Aadigen Inc) is a start-up biopharmaceutical company focused on treating cancer using its novel RNA therapeutics strategy to target aberrant Tumor Suppressor Genes and Oncogenes. Aanastra’s technology has also been used to target other genetic diseases. The technology driving Aanastra’s approach is based on proprietary RNA combined with proprietary peptides that are able to target various tissues and tumors in vivo unlike commonly used strategies for RNA delivery including viral and lipid-based methods..

Aanastra Inc（前身为Aadigen Inc）是一家初创的生物制药公司，专注于使用其新型RNA治疗策略治疗癌症，以靶向异常的肿瘤抑制基因和癌基因。Aanastra的技术也被用于针对其他遗传疾病。推动Aanastra方法的技术基于专有RNA和专有肽，这些肽能够在体内靶向各种组织和肿瘤，这与常用的RNA递送策略（包括基于病毒和脂质的方法）不同。。

Aanastra’s strategy for aberrant Tumor Suppressor Rescue using proprietary mRNA and gene editing of mutated Oncogenes have shown remarkable antitumor effects in animal models of various cancers that have mutated P53, KRAS or BRCA1. The utility of Aanastra’s technology has also been demonstrated outside of cancer in animal models of hemophilia A to normalize Factor VIII levels and in cholesterol lowering applications by targeting PCSK9..

Aanastra使用专有mRNA和突变癌基因的基因编辑来挽救异常肿瘤抑制因子的策略在突变P53，KRAS或BRCA1的各种癌症的动物模型中显示出显着的抗肿瘤作用。Aanastra技术的实用性也已在血友病A动物模型的癌症之外得到证实，可以通过靶向PCSK9使因子VIII水平正常化，并在降低胆固醇的应用中得到证实。。

Aanastra (Los Angeles, CA) works closely with its sister company Divincell SAS (Nimes, France) in the development of its RNA therapeutics. More information on the Company's strategy is available on the Aanastra website at www.aanastra.com and connect with us on LinkedIn.

Aanastra（加利福尼亚州洛杉矶）与其姊妹公司Divincell SAS（法国尼姆）密切合作开发RNA治疗剂。有关公司战略的更多信息，请访问Aanastra网站www.Aanastra.com，并通过LinkedIn与我们联系。

Contact: IR@aanastra.com

联系IR@aanastra.com